Last reviewed · How we verify

Acacia Pharma Ltd — Portfolio Competitive Intelligence Brief

Acacia Pharma Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 5 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
APD421 APD421 phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology / Anesthesia
APD421- Amisulpride for IV injection APD421- Amisulpride for IV injection phase 3 Dopamine antagonist / Antiemetic Dopamine D2 receptor, Dopamine D3 receptor Gastroenterology / Perioperative Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Organon and Co · 2 shared drug classes
  2. University of North Carolina, Chapel Hill · 2 shared drug classes
  3. CCTU · 2 shared drug classes
  4. H. Lundbeck A/S · 2 shared drug classes
  5. Otsuka Pharmaceutical Co., Ltd. · 2 shared drug classes
  6. Shanghai Mental Health Center · 2 shared drug classes
  7. AstraZeneca · 2 shared drug classes
  8. American University of Beirut Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Acacia Pharma Ltd:

Cite this brief

Drug Landscape (2026). Acacia Pharma Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acacia-pharma-ltd. Accessed 2026-06-10.

Related